Jan 8 (Reuters) - Heron Therapeutics Inc:
* HERON THERAPEUTICS - ENROLLMENT COMPLETE IN BOTH PIVOTAL PHASE 3 STUDIES FOR HTX-011; TOP-LINE RESULTS EXPECTED IN H1 OF 2018
* HERON THERAPEUTICS INC - FOR PHASE 3 EFFICACY STUDIES IN BUNIONECTOMY AND HERNIA REPAIR, EXPECTS TO FILE AN NDA WITH FDA IN H2 OF 2018 Source text for Eikon: Further company coverage:
 